The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme

Volumn 41, Issue 7, 2009, Pages 573-579

  Schindler, K ^a   Rieger, A ^a   Tura, A ^a   Gmeinhardt, B ^a   Touzeau Romer V ^a   Haider, D ^a   Pacini, G ^a   Ludvik, B ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; ROSIGLITAZONE;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; BODY COMPOSITION; BONE DENSITY; DOUBLE-BLIND METHOD; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 70149108167     PISSN: None     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1202779     Document Type: Article

References (0)